From the Mayo Center for Sleep Medicine, Departments of Neurology, and Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.
Neurology. 2019 Sep 17;93(12):e1171-e1179. doi: 10.1212/WNL.0000000000008127. Epub 2019 Aug 16.
To determine whether REM sleep without atonia (RSWA) during polysomnography (PSG) predicts phenoconversion in patients with idiopathic REM sleep behavior disorder (iRBD), a prodromal feature of a neurodegenerative disease.
We analyzed RSWA in 60 patients with iRBD, including manual phasic, tonic, and any muscle activity in the submentalis and anterior tibialis muscles and the automated REM atonia index in the submentals. We identified patients who developed parkinsonism or mild cognitive impairment (MCI) during at least 3 years of follow-up after PSG. Kaplan-Meier analysis was performed and receiver operator curves were calculated to determine RSWA cutoffs predicting faster phenoconversion.
Twenty-six (43%) patients developed parkinsonism (n = 17) or MCI (n = 9). Phenoconverters were older at iRBD diagnosis ( = 0.02). Median time to phenoconversion was 3.9 ± 2.5 years. iRBD phenoconverters had significantly more RSWA at diagnosis. Phenoconversion risk from iRBD diagnosis was 20% and 35% at 3 and 5 years, respectively, with greater risk in patients with iRBD with >46.4% any combined RSWA, which increased further to 30% and 55% at 3 and 5 years for patients >65 years of age at diagnosis.
Patients with iRBD with higher amounts of polysomnographic RSWA had a greater risk of developing Parkinson disease or MCI. Patients with older age and higher RSWA amounts had more rapid phenoconversion than younger patients with RBD. Our study suggests that RSWA is a potential biomarker for risk stratification of iRBD phenoconversion that could facilitate prognostication for patients with iRBD.
This study provides Class II evidence that for patients with iRBD, increased RSWA correlates with increased risk for developing parkinsonism or MCI.
确定多导睡眠图(PSG)中 REM 睡眠无张力(RSWA)是否可预测特发性 REM 睡眠行为障碍(iRBD)患者的表型转化,后者是神经退行性疾病的前驱特征。
我们分析了 60 例 iRBD 患者的 RSWA,包括手动相位、强直性和颏下肌和胫骨前肌的任何肌肉活动以及颏下肌的自动 REM 弛缓指数。我们确定了在 PSG 后至少 3 年的随访期间出现帕金森病或轻度认知障碍(MCI)的患者。进行了 Kaplan-Meier 分析,并计算了受试者工作特征曲线,以确定预测更快表型转化的 RSWA 截断值。
26 例(43%)患者出现帕金森病(n=17)或 MCI(n=9)。表型转化者的 iRBD 诊断年龄较大(P=0.02)。中位表型转化时间为 3.9±2.5 年。iRBD 表型转化者的 RSWA 在诊断时显著更高。从 iRBD 诊断开始,表型转化的风险分别为 20%和 35%,在诊断时年龄>65 岁的患者中风险更大,其任何联合 RSWA 均>46.4%,进一步增加到 3 年和 5 年时的 30%和 55%。
iRBD 患者的 PSG RSWA 越多,患帕金森病或 MCI 的风险越大。年龄较大和 RSWA 较高的患者比年轻的 RBD 患者表型转化更快。我们的研究表明,RSWA 是 iRBD 表型转化风险分层的潜在生物标志物,可促进 iRBD 患者的预后。
这项研究提供了 II 级证据,表明对于 iRBD 患者,RSWA 增加与发生帕金森病或 MCI 的风险增加相关。